Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2022; 14(5): 947-958
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.947
Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics
Imaad Said, Hassan Ahad, Adnan Said
Imaad Said, Brown University, Providence, RI 02912, United States
Hassan Ahad, Kansas University, Lawrence, KS 66045, United States
Adnan Said, Division of Gastroenterology and Hepatology, Department of Medicine, William S. Middleton VAMC, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, United States
Author contributions: Said A put forward the study concept and design; all authors did the manuscript writing and editing.
Conflict-of-interest statement: None of the authors have any relevant conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Adnan Said, FAASLD, MD, MS, Professor, Division of Gastroenterology and Hepatology, Department of Medicine, William S. Middleton VAMC, University of Wisconsin School of Medicine and Public Health, 4223 MFCB, 1685 Highland Avenue, Madison, WI 53705, United States. axs@medicine.wisc.edu
Received: March 8, 2021
Peer-review started: March 8, 2021
First decision: March 29, 2021
Revised: April 14, 2021
Accepted: April 15, 2022
Article in press: April 15, 2022
Published online: May 15, 2022
Core Tip

Core Tip: The gut microbiome is intimately linked to nonalcoholic fatty liver disease, cirrhosis and hepatocellular carcinoma. The breakdown of the intestinal barrier in liver disease, innate immune system stimulation and bile acid profile changes are increasingly found in association with these diseases. Manipulation of the microbiome by diet, probiotics, prebiotics and other agents is a promising area of investigation.